12:29 PM EST - Algernon Pharmaceuticals Inc. : Has made the decision to begin production of NP-120 (Ifenprodil) with a new injectable and long acting oral release formulation, in order to be prepared for new U.S. clinical trials for COVID-19 (coronavirus) and acute lung injury (ALI). Algernon Pharmaceuticals Inc.
shares CSE:AGN are trading up $0.13 at $0.28.
